Business Context and Reporting Period
This Form 6-K filing by AC Immune SA covers the month of July 2018. The registrant is a foreign private issuer based in Lausanne, Switzerland, focused on the development of therapeutics for neurodegenerative diseases. The primary purpose of this report is to disclose the completion of a public offering of common shares.
Key Financial Metrics
The filing details a capital raise event rather than operational financial results for a specific period. Key metrics related to the offering include:
- Shares Issued: 7,391,305 common shares initially, plus an additional 1,108,695 shares via the full exercise of the underwriters' option.
- Offering Price: $11.75 per share to the public; $11.045 per share to underwriters.
- Net Proceeds: Approximately $80.9 million from the initial offering and approximately $12.2 million from the option exercise, totaling approximately $93.1 million.
- Debt and Liquidity: The filing does not provide specific data on existing debt levels, operating cash flow, or current liquidity ratios outside of the proceeds from this offering.
Material Changes
The material change disclosed is the significant increase in the Company's cash resources resulting from the equity offering. The filing does not provide comparative financial data (e.g., revenue or profit) against prior periods to assess operational changes.
Guidance, Outlook, and Risks
Management Commentary: The Company entered into an underwriting agreement with Jefferies LLC, Leerink Partners LLC, and UBS Securities LLC. The proceeds are intended to fund the Company's operations and strategic initiatives, though specific allocation details are not provided in this text.
Lock-Up Agreements: The Company, its directors, and executive officers have agreed to a 90-day lock-up period following the Underwriting Agreement date, restricting the sale or transfer of securities.
Risks and Contingencies: The filing notes customary representations, warranties, and indemnification obligations within the Underwriting Agreement. It does not explicitly list new operational risks or contingencies beyond standard underwriting terms.
Investor Verification Checklist
- Verify the final closing date and total net proceeds received after all offering expenses.
- Review the Company's most recent Form 20-F or quarterly reports to assess pre-offering cash runway and burn rate.
- Confirm the specific intended use of the approximately $93.1 million in proceeds (e.g., clinical trial funding, R&D expansion).
- Monitor the expiration of the 90-day lock-up period for potential selling pressure from insiders.